doi: 10.1016/j.intimp.2023.111127 95 MuYLuoLBWuSJGaoYQinXLZhaoJet al
Gregory AC 2nd, Kempen JH, Daniel E, Kamaz RO, Foster CS, Jabs DA, et al
Adverse Events by System Gastrointestinal Events GI adverse events are the most commonly reported class across all retatrutide clinical trials
By distribution channel , the online pharmacies segment is expected to grow at the fastest CAGR of 20.8% from 2026 to 2035, since they provide greater convenience, privacy, and even low prices to patients purchasing GLP-1-based treatments, especially for weight loss, where a patient may not want to visit a physical pharmacy and purchase the drug discreetly
In 2023, Gubra had approx